{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:01Z","timestamp":1791765361730,"version":"4.3.4"},"reference-count":75,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2021,1,25]]},"DOI":"10.1253\/circj.cj-20-0406","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T22:06:45Z","timestamp":1608242805000},"page":"130-138","source":"Crossref","is-referenced-by-count":107,"title":["Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease\u3000\u2015 Japanese Guideline on the Management of Asymptomatic Hyperuricemia \u2015"],"prefix":"10.1253","volume":"85","author":[{"given":"Ichiro","family":"Hisatome","sequence":"first","affiliation":[{"name":"Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peili","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Miake","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Tottori University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikri","family":"Taufiq","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, Sultan Agung Islamic University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endang","family":"Mahati","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapy, Faculty of Medicine, Diponegoro University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nani","family":"Maharani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapy, Faculty of Medicine, Diponegoro University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulistiyati Bayu","family":"Utami","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Intensive Care Unit and Department of Cardiology, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udin","family":"Bahrudin","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruaki","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Department of Biological Regulation, Tottori University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: Second edition. <i>Nucleosides Nucleotides Nucleic Acids<\/i> 2011; 30: 1018\u20131029.","DOI":"10.1080\/15257770.2011.596496"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis Care Res (Hoboken)<\/i> 2020; 72: 744\u2013760.","DOI":"10.1002\/acr.24180"},{"key":"3","unstructured":"3. Hisatome I, Ichida K, Mineo I, Ohtahara A, Ogino K, Kuwabara M, et al. Japanese Society of Gout and Uric &amp; Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition. <i>Gout and Uric &amp; Nucleic Acids<\/i> 2020; 44: sp-1\u2013sp-40."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Allen DJ, Milosovich G, Mattocks AM. Inhibition of monosodium urate needle crystal growth. <i>Arthritis Rheum<\/i> 1965; 8: 1123\u20131133.","DOI":"10.1002\/art.1780080611"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Loeb JN. The influence of temperature on the solubility of monosodium urate. <i>Arthritis Rheum<\/i> 1972; 15: 189\u2013192.","DOI":"10.1002\/art.1780150209"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Seegmiller JE. The acute attack of gouty arthritis. <i>Arthritis Rheum<\/i> 1965; 8: 714\u2013725.","DOI":"10.1002\/art.1780080431"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: Risks and consequences in the Normative Aging Study. <i>Am J Med<\/i> 1987; 82: 421\u2013426.","DOI":"10.1016\/0002-9343(87)90441-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: A randomized trial. <i>Am J Kidney Dis<\/i> 2018; 72: 798\u2013810.","DOI":"10.1053\/j.ajkd.2018.06.028"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. <i>Arthritis Rheum<\/i> 2002; 47: 610\u2013613.","DOI":"10.1002\/art.10792"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. <i>Nat Commun<\/i> 2012; 3: 764.","DOI":"10.1038\/ncomms1756"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population. <i>Sci Transl Med<\/i> 2009; 1: 5ra11.","DOI":"10.1126\/scitranslmed.3000237"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. <i>Arthritis Care Res (Hoboken)<\/i> 2011; 63: 102\u2013110.","DOI":"10.1002\/acr.20344"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al. High serum uric acid and increased risk of type 2 diabetes: A systemic review and meta-analysis of prospective cohort studies. <i>PLoS One<\/i> 2013; 8: e56864.","DOI":"10.1371\/journal.pone.0056864"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, et al. Serum uric acid levels and risk of metabolic syndrome: A dose-response meta-analysis of prospective studies. <i>J Clin Endocrinol Metab<\/i> 2015; 100: 4198\u20134207.","DOI":"10.1210\/jc.2015-2527"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jensen T, Niwa K, Hisatome I, Kanbay M, Andres-Hernando A, Roncal-Jimenez CA, et al. Increased serum uric acid over five years is a risk factor for developing fatty liver. <i>Sci Rep<\/i> 2018; 8: 11735.","DOI":"10.1038\/s41598-018-30267-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: A meta-analysis of 15 cohort studies. <i>PLoS One<\/i> 2014; 9: e100801.","DOI":"10.1371\/journal.pone.0100801"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li M, Hu X, Fan Y, Li K, Zhang X, Hou W, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. <i>Sci Rep<\/i> 2016; 6: 19520.","DOI":"10.1038\/srep19520"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, et al. Uric acid and risk of heart failure: A systematic review and meta-analysis. <i>Eur J Heart Fail<\/i> 2014; 16: 15\u201324.","DOI":"10.1093\/eurjhf\/hft132"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kuwabara M, Niwa K, Nishihara S, Nishi Y, Takahashi O, Kario K, et al. Hyperuricemia is an independent competing risk factor for atrial fibrillation. <i>Int J Cardiol<\/i> 2017; 231: 137\u2013142.","DOI":"10.1016\/j.ijcard.2016.11.268"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels: The Third National Health and Nutrition Examination Survey. <i>Rheumatology (Oxford)<\/i> 2008; 47: 713\u2013717.","DOI":"10.1093\/rheumatology\/ken066"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. <i>Nature<\/i> 2002; 417: 447\u2013452.","DOI":"10.1038\/nature742"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. <i>Am J Hypertens<\/i> 1996; 9: 746\u2013752.","DOI":"10.1016\/0895-7061(96)00098-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Toyoki D, Shibata S, Kuribayashi-Okuma E, Xu N, Ishizawa K, Hosoyamada M, et al. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. <i>Am J Physiol Renal Physiol<\/i> 2017; 313: F826\u2013F834.","DOI":"10.1152\/ajprenal.00012.2017"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: From molecular background to clinical perspectives. <i>Atherosclerosis<\/i> 2018; 278: 226\u2013231.","DOI":"10.1016\/j.atherosclerosis.2018.10.007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Vane JR, Angg\u00e5rd EE, Botting RM. Regulatory functions of the vascular endothelium. <i>N Engl J Med<\/i> 1990; 323: 27\u201336.","DOI":"10.1056\/NEJM199007053230106"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ross R. Atherosclerosis: An inflammatory disease. <i>N Engl J Med<\/i> 1999; 340: 115\u2013126.","DOI":"10.1056\/NEJM199901143400207"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Maruhashi T, Nakashima A, Soga J, Fujimura N, Idei N, Mikami S, et al. Hyperuricemia is independently associated with endothelial dysfunction in postmenopausal women but not in premenopausal women. <i>BMJ Open<\/i> 2013; 3: e003659.","DOI":"10.1136\/bmjopen-2013-003659"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. <i>Am J Cardiol<\/i> 2005; 96: 1576\u20131578.","DOI":"10.1016\/j.amjcard.2005.07.068"},{"key":"29","unstructured":"29. Warning WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human vascular bed. <i>Br J Clin Pharmacol<\/i> 2000; 59: 511."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. <i>Am J Physiol Renal Physiol<\/i> 2006; 290: F625\u2013F631.","DOI":"10.1152\/ajprenal.00140.2005"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32. Mishima M, Hamada T, Maharani N, Ikeda N, Onohara T, Notsu T, et al. Effects of uric acid on the NO production of HUVECs and its restoration by urate lowering agents. <i>Drug Res (Stuttg)<\/i> 2016; 66: 270\u2013274.","DOI":"10.1055\/s-0035-1569405"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. <i>J Biol Chem<\/i> 2008; 283: 26834\u201326838.","DOI":"10.1074\/jbc.C800156200"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34. Nakamura M, Anzai N, Jutabha P, Sato H, Sakurai H, Ichida K. Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. <i>J Pharmacol Sci<\/i> 2010; 114: 115\u2013118.","DOI":"10.1254\/jphs.10064SC"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35. Maharani N, Kuwabara M, Hisatome I. Hyperuricemia and atrial fibrillation. <i>Int Heart J<\/i> 2016; 57: 395\u2013399.","DOI":"10.1536\/ihj.16-192"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36. Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. <i>Am J Nephrol<\/i> 2005; 25: 425\u2013433.","DOI":"10.1159\/000087713"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37. Taufiq F, Maharani N, Li P, Kurata Y, Ikeda N, Kuwabara M, et al. Uric acid-induced enhancements of Kv1.5 protein expression and channel activity via the Akt-HSF1-Hsp70 Pathway in HL-1 atrial myocytes. <i>Circ J<\/i> 2019; 83: 718\u2013726.","DOI":"10.1253\/circj.CJ-18-1088"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. <i>J Am Soc Nephrol<\/i> 2005; 16: 3553\u20133562.","DOI":"10.1681\/ASN.2005050572"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39. Sessa WC. eNOS at a glance. <i>J Cell Sci<\/i> 2004; 117: 2427\u20132429.","DOI":"10.1242\/jcs.01165"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40. Li P, Zhang L, Zhang M, Zhou C, Lin N. Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction. <i>Int J Mol Med<\/i> 2016; 37: 989\u2013997.","DOI":"10.3892\/ijmm.2016.2491"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41. Zhou Y, You H, Zhang A, Jiang X, Pu Z, Xu G, et al. Lipoxin A4 attenuates uric acid-activated, NADPH oxidase-dependent oxidative stress by interfering with translocation of p47phox in human umbilical vein endothelial cells. <i>Exp Ther Med<\/i> 2020; 20: 1682\u20131692.","DOI":"10.3892\/etm.2020.8812"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: Molecular mechanisms and pathophysiological implications. <i>J Physiol<\/i> 2004; 555: 589\u2013606.","DOI":"10.1113\/jphysiol.2003.055913"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43. Forstermann U, Sessa WC. Nitric oxide synthases: Regulation and function. <i>Eur Heart J<\/i> 2012; 33: 829\u2013837, 837a\u2013837d.","DOI":"10.1093\/eurheartj\/ehr304"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44. Furuhashi M, Matsumoto M, Tanaka M, Moniwa N, Murase T, Nakamura T, et al. Plasma xanthine oxidoreductase activity as a novel biomarker of metabolic disorders in a general population. <i>Circ J<\/i> 2018; 82: 1892\u20131899.","DOI":"10.1253\/circj.CJ-18-0082"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. <i>J Biol Chem<\/i> 1999; 274: 4985\u20134994.","DOI":"10.1074\/jbc.274.8.4985"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, et al. Superoxide and peroxynitrite in atherosclerosis. <i>Proc Natl Acad Sci USA<\/i> 1994; 91: 1044\u20131048.","DOI":"10.1073\/pnas.91.3.1044"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. <i>Curr Pharm Des<\/i> 2005; 11: 4145\u20134151.","DOI":"10.2174\/138161205774913255"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48. Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, et al. Peroxidase properties of extracellular superoxide dismutase: Role of uric acid in modulating in vivo activity. <i>Arterioscler Thromb Vasc Biol<\/i> 2002; 22: 1402\u20131408.","DOI":"10.1161\/01.ATV.0000027524.86752.02"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49. Sugihara S, Hisatome I, Kuwabara M, Niwa K, Maharani N, Kato M, et al. Depletion of uric acid due to SLC22A12 (URAT1) loss-of-function mutation causes endothelial dysfunction in hypouricemia. <i>Circ J<\/i> 2015; 79: 1125\u20131132.","DOI":"10.1253\/circj.CJ-14-1267"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50. Ishikawa I. Acute renal failure with severe loin pain and patchy renal ischemia after anaerobic exercise in patients with or without renal hypouricemia. <i>Nephron<\/i> 2002; 91: 559\u2013570.","DOI":"10.1159\/000065013"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA study. <i>Hypertension<\/i> 2000; 36: 1072\u20131078.","DOI":"10.1161\/01.HYP.36.6.1072"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52. Kuwabara M, Hisatome I, Niwa K, Bjornstad P, Roncal-Jimenez CA, Andres-Hernando A, et al. The optimal range of serum uric acid for cardiometabolic diseases: A 5-year Japanese cohort study. <i>J Clin Med<\/i> 2020; 9: 942.","DOI":"10.3390\/jcm9040942"},{"key":"52","doi-asserted-by":"crossref","unstructured":"53. Sivera F, Andr\u00e9s M, Carmona L, Kydd AS, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Ann Rheum Dis<\/i> 2014; 73: 328\u2013335.","DOI":"10.1136\/annrheumdis-2013-203325"},{"key":"53","doi-asserted-by":"crossref","unstructured":"54. Levy G, Shi JM, Cheetham TC, Rashid N. Urate-lowering therapy in moderate to severe chronic kidney disease. <i>Perm J<\/i> 2018; 22: 17\u2013142.","DOI":"10.7812\/TPP\/17-142"},{"key":"54","doi-asserted-by":"crossref","unstructured":"55. Abeles AM, Pillinger MH. Gout and cardiovascular disease: Crystallized confusion. <i>Curr Opin Rheumatol<\/i> 2019; 31: 118\u2013124.","DOI":"10.1097\/BOR.0000000000000585"},{"key":"55","unstructured":"57. Fukui T, Yamaguchi N. Minds handbook for clinical practice guideline development. Tokyo: Japanese Minds Guideline Center, Japan Council for Quality Health Care, 2014."},{"key":"56","doi-asserted-by":"crossref","unstructured":"58. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. <i>Clin J Am Soc Nephrol<\/i> 2010; 5: 1388\u20131393.","DOI":"10.2215\/CJN.01580210"},{"key":"57","doi-asserted-by":"crossref","unstructured":"59. Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, et al. Clinical outcome of hyperuricemia in IgA nephropathy: A retrospective cohort study and randomized controlled trial. <i>Kidney Blood Press Res<\/i> 2012; 35: 153\u2013160.","DOI":"10.1159\/000331453"},{"key":"58","doi-asserted-by":"crossref","unstructured":"60. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. <i>Clin Exp Nephrol<\/i> 2014; 18: 876\u2013884.","DOI":"10.1007\/s10157-014-0935-8"},{"key":"59","doi-asserted-by":"crossref","unstructured":"61. Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. <i>Clin Endocrinol (Oxf)<\/i> 2015; 83: 475\u2013482.","DOI":"10.1111\/cen.12673"},{"key":"60","doi-asserted-by":"crossref","unstructured":"62. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, et al. Efficacy of Febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial. <i>Am J Kidney Dis<\/i> 2015; 66: 945\u2013950.","DOI":"10.1053\/j.ajkd.2015.05.017"},{"key":"61","doi-asserted-by":"crossref","unstructured":"63. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. <i>Am J Kidney Dis<\/i> 2006; 47: 51\u201359.","DOI":"10.1053\/j.ajkd.2005.10.006"},{"key":"62","doi-asserted-by":"crossref","unstructured":"64. Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of Febuxostat on renal function in gout patients with moderate-to-severe renal impairment. <i>Arthritis Rheumatol<\/i> 2016; 68: 2035\u20132043.","DOI":"10.1002\/art.39654"},{"key":"63","doi-asserted-by":"crossref","unstructured":"65. Terawaki H, Nakayama M, Miyazawa E, Murata Y, Nakayama K, Matsushima M, et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: The Gonryo study. <i>Clin Exp Nephrol<\/i> 2013; 17: 549\u2013553.","DOI":"10.1007\/s10157-012-0742-z"},{"key":"64","doi-asserted-by":"crossref","unstructured":"66. MacIsaac RL, Salatzki J, Higgins P, Walters MR, Padmanabhan S, Dominiczak AF, et al. Allopurinol and cardiovascular outcomes in adults with hypertension. <i>Hypertension<\/i> 2016; 67: 535\u2013540.","DOI":"10.1161\/HYPERTENSIONAHA.115.06344"},{"key":"65","doi-asserted-by":"crossref","unstructured":"67. Gois PHF, Souza ERM. Pharmacotherapy for hyperuricemia in hypertensive patients. <i>Cochrane Database Syst Rev<\/i> 2017; 4: CD008652.","DOI":"10.1002\/14651858.CD008652.pub3"},{"key":"66","doi-asserted-by":"crossref","unstructured":"68. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure: Results of the OPT-CHF study. <i>J Am Coll Cardiol<\/i> 2008; 51: 2301\u20132309.","DOI":"10.1016\/j.jacc.2008.01.068"},{"key":"67","doi-asserted-by":"crossref","unstructured":"69. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. <i>Circulation<\/i> 2015; 131: 1763\u20131771.","DOI":"10.1161\/CIRCULATIONAHA.114.014536"},{"key":"68","doi-asserted-by":"crossref","unstructured":"70. Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. <i>Eur Heart J<\/i> 2019; 40: 1778\u20131786.","DOI":"10.1093\/eurheartj\/ehz119"},{"key":"69","doi-asserted-by":"crossref","unstructured":"71. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. <i>N Engl J Med<\/i> 2018; 378: 1200\u20131210.","DOI":"10.1056\/NEJMoa1710895"},{"key":"70","doi-asserted-by":"crossref","unstructured":"72. Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: Population-based cohort study. <i>Circulation<\/i> 2018; 138: 1116\u20131126.","DOI":"10.1161\/CIRCULATIONAHA.118.033992"},{"key":"71","unstructured":"73. Foody J, Turpin RS, Tidwell BA, Lawrence D, Schulman KL. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. <i>Am Health Drug Benefits<\/i> 2017; 10: 393\u2013401."},{"key":"72","doi-asserted-by":"crossref","unstructured":"74. MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. <i>BMJ Open<\/i> 2014; 4: e005354.","DOI":"10.1136\/bmjopen-2014-005354"},{"key":"73","doi-asserted-by":"crossref","unstructured":"75. Bubb MR. Excess deaths upon cessation of xanthine oxidase inhibitor treatment-Data from the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial: Comment on the Article by Choi et al. <i>Arthritis Rheumatol<\/i> 2019; 71: 1391\u20131392.","DOI":"10.1002\/art.40914"},{"key":"74","doi-asserted-by":"crossref","unstructured":"76. Johnson TA, Kamatani N, Kuwabara M. Xanthine oxidase inhibitor withdrawal syndrome? Comment on the Article by Choi et al. <i>Arthritis Rheumatol<\/i> 2019; 71: 1966\u20131967.","DOI":"10.1002\/art.41066"},{"key":"75","doi-asserted-by":"crossref","unstructured":"77. Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: A systematic review and meta-analysis. <i>JACC Heart Fail<\/i> 2015; 3: 647\u2013653.","DOI":"10.1016\/j.jchf.2015.03.008"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/85\/2\/85_CJ-20-0406\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T03:25:08Z","timestamp":1611977108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/85\/2\/85_CJ-20-0406\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-20-0406","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]}}}